Minerva Neurosciences, Inc: Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Company to Host Webcast Wednesday, April 13, 2022 at 11am ETWALTHAM, Mass., April 07, 2022(NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system

Related Keywords

Miami ,Florida ,United States ,Leucht ,Baden Wüberg ,Germany ,Helen Shik ,Phil Harvey ,Leonardm Miller ,Minerva Neurosciences ,Billy Dunn ,Remy Luthringer ,Tiffany Farchione ,Frederick Ahlholm ,Drug Administration ,Nasdaq ,Office Of Neuroscience ,University Of Miami Miller School Medicine ,Shik Communications ,Minerva Neurosciences Inc ,Behavioral Sciences ,Division Of Psychiatry ,Company To Host Webcast ,Host Webcast Wednesday ,Executive Chairman ,Chief Executive Officer ,Geoff Race ,Miami Miller School ,Private Securities Litigation Reform Act ,Aminerva ,Neurosciences ,Rovides ,Update ,Rom ,Type ,Meeting ,Text ,Steps ,Preparation ,Submission ,Drug ,Application ,Roluperidone ,Treatment ,Negative ,Symptoms ,Schizophrenia ,